272 related articles for article (PubMed ID: 33721148)
1. Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.
Hetterich M; Gerken M; Ortmann O; Inwald EC; Klinkhammer-Schalke M; Eggemann H; Ignatov A
Breast Cancer Res Treat; 2021 Jun; 187(3):715-727. PubMed ID: 33721148
[TBL] [Abstract][Full Text] [Related]
2. Micrometastases or isolated tumor cells and the outcome of breast cancer.
de Boer M; van Deurzen CH; van Dijck JA; Borm GF; van Diest PJ; Adang EM; Nortier JW; Rutgers EJ; Seynaeve C; Menke-Pluymers MB; Bult P; Tjan-Heijnen VC
N Engl J Med; 2009 Aug; 361(7):653-63. PubMed ID: 19675329
[TBL] [Abstract][Full Text] [Related]
3. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
Andersson Y; Bergkvist L; Frisell J; de Boniface J
Breast Cancer Res Treat; 2018 Sep; 171(2):359-369. PubMed ID: 29846847
[TBL] [Abstract][Full Text] [Related]
4. Axillary and systemic treatment of patients with breast cancer and micrometastatic disease or isolated tumor cells in the sentinel lymph node.
Maaskant-Braat AJ; Voogd AC; van de Poll-Franse LV; Coebergh JW; Nieuwenhuijzen GA
Breast; 2012 Aug; 21(4):524-8. PubMed ID: 22516371
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study.
Tvedskov TF; Jensen MB; Ejlertsen B; Christiansen P; Balslev E; Kroman N
Breast Cancer Res Treat; 2015 Oct; 153(3):599-606. PubMed ID: 26341752
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
[TBL] [Abstract][Full Text] [Related]
7. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
Houvenaeghel G; Boher JM; Reyal F; Cohen M; Garbay JR; Classe JM; Rouzier R; Giard S; Faure C; Charitansky H; Tunon de Lara C; Daraï E; Hudry D; Azuar P; Gimbergues P; Villet R; Sfumato P; Lambaudie E
Eur J Cancer; 2016 Nov; 67():106-118. PubMed ID: 27640137
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of sentinel lymph node biopsy prior to axillary lymph node dissection: the role of isolated tumor cells/micrometastases and multifocality/multicentricity-a retrospective study of 1214 breast cancer patients.
Schröder L; Fricker R; Stein RG; Rink T; Fitz H; Blasius S; Wöckel A; Müller T
Arch Gynecol Obstet; 2018 Jun; 297(6):1509-1515. PubMed ID: 29594495
[TBL] [Abstract][Full Text] [Related]
9. The evolution of the sentinel node procedure in the treatment of breast cancer.
Tvedskov TF
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
[TBL] [Abstract][Full Text] [Related]
10. The Sentinel Node with Isolated Breast Tumor Cells or Micrometastases. Benefits and Risks of Axillary Dissection.
Madekivi V; Boström P; Aaltonen R; Vahlberg T; Salminen E
Anticancer Res; 2017 Jul; 37(7):3757-3762. PubMed ID: 28668871
[TBL] [Abstract][Full Text] [Related]
11. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
12. One Step Nucleic Acid Amplification (OSNA) positive micrometastases and additional histopathological NSLN metastases: Results from a single institution over 53 months.
Babar M; Madani R; Jackson P; Layer GT; Kissin MW; Irvine TE
Surgeon; 2016 Apr; 14(2):76-81. PubMed ID: 25444440
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782
[TBL] [Abstract][Full Text] [Related]
14. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
[TBL] [Abstract][Full Text] [Related]
15. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
[TBL] [Abstract][Full Text] [Related]
16. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.
Kahn HJ; Hanna WM; Chapman JA; Trudeau ME; Lickley HL; Mobbs BG; Murray D; Pritchard KI; Sawka CA; McCready DR; Marks A
Breast J; 2006; 12(4):294-301. PubMed ID: 16848838
[TBL] [Abstract][Full Text] [Related]
17. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of micrometastases and isolated tumor cells in the sentinel node at early stage breast cancer].
Cordero García JM; Palomar Muñoz A; Delgado Portela M; García Vicente AM; Pilkington Woll JP; Poblete García VM; Bellón Guardia ME; Pardo García R; Rabadán Ruiz L; Soriano Castrejón A
Rev Esp Med Nucl Imagen Mol; 2012; 31(2):78-82. PubMed ID: 21658817
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of isolated tumor cells and micrometastases in axillary lymph nodes in breast cancer.
Madsen EV; Elias SG; van Dalen T; van Oort PM; van Gorp J; Gobardhan PD; Bongers V
Breast; 2013 Oct; 22(5):748-52. PubMed ID: 23313060
[TBL] [Abstract][Full Text] [Related]
20. Axillary node staging for microinvasive breast cancer: is it justified?
Lyons JM; Stempel M; Van Zee KJ; Cody HS
Ann Surg Oncol; 2012 Oct; 19(11):3416-21. PubMed ID: 22576061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
